Piperazine-Based CCR5 Antagonists as HIV-1 Inhibitors. II. Discovery of 1-[(2,4-Dimethyl-3-pyridinyl)carbonyl]-4- methyl-4-[3(S)-methyl-4-[1(S)-[4-(trifluoro- methyl)phenyl]ethyl]-1-piperazinyl]- piperidine N1-Oxide (Sch-350634), an Orally Bioavailable, Potent CCR5 Antagonist

Autor: Tagat, J. R., Steensma, R. W., McCombie, S. W., Nazareno, D. V., Lin, S.-I., Neustadt, B. R., Cox, K., Xu, S., Wojcik, L., Murray, M. G., Vantuno, N., Baroudy, B. M., Strizki, J. M.

Publikováno v: Journal of Medicinal Chemistry; October 2001, Vol. 44 Issue: 21 p3343-3346, 4p

Piperazine-based CCR5 antagonists as HIV-1 inhibitors. II. Discovery of 1-[(2,4-dimethyl-3-pyridinyl)carbonyl]-4- methyl-4-[3(S)-methyl-4-[1(S)-[4-(trifluoromethyl)phenyl]ethyl]-1-piperazinyl]- piperidine N1-oxide (Sch-350634), an orally bioavailable, potent CCR5 antagonist.

Autor: Tagat JR; Departments of Chemical Research, Drug Metabolism & Pharmacokinetics, and Antiviral Therapy, Schering-Plough Research Institute, K-15-2B-2800, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, USA. jayaram.tagat@spcorp.com, Steensma RW, McCombie SW, Nazareno DV, Lin SI, Neustadt BR, Cox K, Xu S, Wojcik L, Murray MG, Vantuno N, Baroudy BM, Strizki JM

Publikováno v: Journal of medicinal chemistry [J Med Chem] 2001 Oct 11; Vol. 44 (21), pp. 3343-6.